Quest Diagnostics (DGX)

Common Stock

Sell: $171.10|Buy: $195.00|Change: 3.47 (-1.88%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

$184.88

Previous close

$184.64

Trade high

$186.455

Volume

1,583,501

Year high

$197.55

Year low

$148.70

Dividend yield

1.71%

Market capitalisation

$20.15 bn

P/E ratio

21.67

ISIN

US74834L1008

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Dividends

	Previous	Latest
Record date	07/07/2025	03/10/2025
Ex-dividend date	07/07/2025	03/10/2025
Payment date	21/07/2025	20/10/2025
Amount	$0.80	$0.80

Performance 22/10/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Quest Diagnostics	- 1.88
More...

Company profile

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.